Archive for May, 2006
« Previous EntriesDesvenlafaxine Succinate (DVS-233) Phase 3 Data Show Significant Improvement In Symptoms Of Depression In Adult Patients Versus Placebo
Saturday, May 27th, 2006Wyeth Pharmaceuticals,a division of Wyeth (NYSE: WYE), this week presented for the first timephase 3 data and results from other studies concerning its investigationaldrug for major depressive disorder (MDD), desvenlafaxine succinate(DVS-233), a novel serotonin-norepinephrine reuptake inhibitor (SNRI) atthe 2006 American Psychiatric Association Annual Meeting in Toronto. [click link for full article]
Patients, Be Patient: Brain Images Suggest New Therapy For Severe Depression Can Take Months To Work
Friday, May 26th, 2006It takes time - between three and 12 months - before a new type of therapy for treatment-resistant depression starts to benefit patients, according to new preliminary brain scan research that confirms earlier observations by psychiatrists about vagal nerve stimulation. [click link for full article]
Patients, Be Patient: Brain Images Suggest New Therapy For Severe Depression Can Take Months To Work
Friday, May 26th, 2006It takes time - between three and 12 months - before a new type of therapy for treatment-resistant depression starts to benefit patients, according to new preliminary brain scan research that confirms earlier observations by psychiatrists about vagal nerve stimulation. [click link for full article]
Listening To Music Can Reduce Chronic Pain And Depression By Up To A Quarter
Thursday, May 25th, 2006Listening to music can reduce chronic pain by up to 21 per cent and depression by up to 25 per cent, according to a paper in the latest UK-based Journal of Advanced Nursing. It can also make people feel more in control of their pain and less disabled by their condition. Researchers carried out a controlled clinical trial with sixty people, dividing them into two music groups and a control group. [click link for full article]
Study Identifies Predictors Of Bipolar Disorder Risk
Tuesday, May 23rd, 2006A new study presented today at the159th Annual Scientific Meeting of the American Psychiatric Association(APA) in Toronto, Canada identified five predictors for bipolar disorderrisk in patients who have been unsuccessfully treated with antidepressants. [click link for full article]
Corcept Therapeutics Completes Enrollment In Second Phase 3 Study For Treating Psychotic Major Depression
Tuesday, May 23rd, 2006CorceptTherapeutics Incorporated (Nasdaq: CORT) announced today that it completedpatient enrollment in Corcept 09, the second of three Phase 3 clinicaltrials in which CORLUX(R) (mifepristone) is being evaluated for treatingthe psychotic features of psychotic major depression (PMD). [click link for full article]
Women Exposed To Violence From Partner Have Higher Rates Of Depression, Adverse Health, Study Says
Monday, May 22nd, 2006Women who have been exposed to intimate partner violence, or IPV, have significantly higher rates of depression, social isolation and physical health symptoms than other women, according to a study published in the June issue of the American Journal of Preventive Medicine, [click link for full article]
Botox Into Frown Lines Can Help Patients With Major Depression
Monday, May 22nd, 2006A trial carried out by Dr. Eric Finzi and Dr. Erika Wasserman found that treating clinically depressed patients with botox on the frown lines of their faces actually got rid of their depression. In their abstract report, found in the journal Dermatologic Surgery, the researchers indicate that major depression is a common and serious disease. Major depression is sometime resistant to drug therapy and psychotherapeutic treatment approaches. [click link for full article]
ABILIFY® (aripiprazole) Effictive As Maintenance Therapy In Adults With Bipolar I Disorder Following Treatment For A Recent Manic Or Mixed Episode
Monday, May 22nd, 2006Maintenance therapy with the Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. [click link for full article]
What Does Prozac Target?
Thursday, May 18th, 2006Researchers at Cold Spring Harbor Laboratory on Long Island have identified which among several different kinds of cells in the brain is the chief target of the widely prescribed antidepressant Prozac. This discovery might enable a new generation of more specific treatments for depression, with fewer side effects, to be developed. [click link for full article]
« Previous Entries